Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma.

Target Oncol · 2025 · PMC12307566 · PMID 40332715

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

On the basis of the population PK and exposure–response analysis, there was a positive trend for overall response rate (ORR) with increasing teclistamab exposure, with a plateau observed at the RP2D and no exposure–response trend for safety [ 19 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.